NCT03007823View on ClinicalTrials.gov

High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

December 1, 2017

Study Completion Date

June 1, 2019

Conditions
Melanoma
Interventions
BIOLOGICAL

High-activity natural killer

Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.

Trial Locations (1)

510665

Fuda cancer institute of Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT03007823 - High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma | Biotech Hunter | Biotech Hunter